Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study - Scorecard - MDSpire

Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study

  • By

  • Wenwen Cui

  • Lihang Xing

  • Zhenzhen Li

  • Xinjun Li

  • Junzhi Li

  • July 8, 2026

  • 0 min

Share

Clinical Scorecard: Clinical, Pathological, Proliferative, Molecular, and Prognostic Features of Differentiated High-Grade Thyroid Carcinoma: A Retrospective Multicenter Analysis

At a Glance

CategoryDetail
ConditionDifferentiated High-Grade Thyroid Carcinoma (DHGTC)
Key MechanismsHigh-grade pathological features, including increased mitotic activity and tumor necrosis; molecular abnormalities such as BRAF mutations.
Target PopulationPatients diagnosed with DHGTC, median age 61 years.
Care SettingTertiary medical centers

Key Highlights

  • DHGTC is characterized by marked invasiveness and high-grade features.
  • All cases exhibited a Ki-67 proliferation index of ≥10%, with some ≥20%.
  • BRAF abnormalities were found in 9 cases, with additional mutations in TERT and p53 in some patients.
  • During follow-up, 4 patients experienced recurrence or metastasis, and 2 patients died.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of DHGTC requires the presence of tumor necrosis and/or ≥5 mitoses per 2 mm².

Management

  • Individualized treatment based on histological and molecular characteristics.

Monitoring & Follow-up

  • Postoperative follow-up to evaluate prognosis and detect recurrence.

Risks

  • High risk of recurrence and metastasis associated with DHGTC.

Patient & Prescribing Data

19 patients with pathologically confirmed DHGTC.

Treatment response and long-term prognosis remain to be fully defined.

Clinical Best Practices

  • Utilize the latest WHO classification criteria for accurate diagnosis.
  • Consider molecular testing for BRAF and other mutations in DHGTC cases.
  • Monitor Ki-67 proliferation index as part of risk stratification.

Related Resources & Content

Original Source(s)

Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study

  • by Wenwen Cui, Lihang Xing, Zhenzhen Li, Xinjun Li, Junzhi Li

  • July 8, 2026

Related Content

Innovative use of therapeutic antibodies in lung cancer: the current landscape of ADCs and other antibody-based therapies

Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.

  • by

  • July 7, 2026

  • 8 min
Case Report: A case of incidentally discovered isolated gastric plasmacytoma